rs1800789 — FGB -249G>A

The Fibrinogen Quieter — How the -249G>A Variant Lowers Clotting Protein Levels

The fibrinogen beta chain (FGB) gene sits at the heart of the coagulation cascade. Fibrinogen, produced in the liver, circulates at 2-4 g/L and is cleaved by thrombin to form fibrin — the structural scaffold of every blood clot. Higher fibrinogen concentrations are an established independent cardiovascular risk factor: each 1 g/L increase in plasma fibrinogen is associated with roughly 25% higher cardiovascular mortality in prospective cohorts. The rs1800789 promoter variant, located approximately 249 base pairs upstream of the FGB transcription start site, is notable because its minor allele appears to reduce fibrinogen production¹¹ its minor allele appears to reduce fibrinogen production
this is the opposite of the better-known FGB promoter variants rs1800787 (-148C>T) and rs1800790 (-455G>A), which both raise fibrinogen, placing it in the minority of FGB variants with a potentially beneficial cardiovascular effect.

The Mechanism

The rs1800789 variant (NC_000004.12:g.154561591G>A) lies in the upstream regulatory region of FGB on chromosome 4q31. The FGB gene is expressed on the plus strand, and the reference allele is G; the minor allele is A (historically described as -249C>T in the older coding-strand notation, where C was the reference and T the minor allele before full plus-strand standardization). This upstream position falls within transcription factor binding motifs that govern how vigorously the liver responds to interleukin-6 (IL-6), the primary cytokine driver of FGB expression during acute-phase reactions.

A large GWAS in 22,096 Europeans²² A large GWAS in 22,096 Europeans
Dehghan A et al. Association of novel genetic loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet. 2009;2(2):125-33. identified rs1800789 as the strongest genetic signal for circulating fibrinogen concentration at genome-wide significance (p=1.8×10⁻³⁰), indicating a highly reproducible effect on FGB expression. The direction of effect — reduced fibrinogen with the A allele — is consistent with a promoter-weakening variant that attenuates the liver's fibrinogen production response, though the precise transcription factor interaction has not been fully characterized.

The Evidence

The cardiovascular implications were directly examined in a Greek case-control study of 305 CAD patients versus 305 controls³³ Greek case-control study of 305 CAD patients versus 305 controls
Theodoraki EV et al. Fibrinogen beta variants confer protection against coronary artery disease in a Greek case-control study. BMC Med Genet. 2010;11:14.. Carriers of the minor A allele showed a significantly lower risk of coronary artery disease, with homozygous minor carriers achieving an odds ratio of 0.44 (95% CI: 0.21–0.94, p=0.039). The study estimated that minor allele homozygotes reduce their CAD risk by approximately 50% compared to GG homozygotes — a striking effect size for a common promoter variant.

Complementing this, a Taiwanese community-based study of 480 participants⁴⁴ a Taiwanese community-based study of 480 participants
Wu FY et al. Evaluation of single nucleotide polymorphisms in 6 candidate genes and carotid intima-media thickness in community-dwelling residents. PLoS One. 2020;15(3):e0230129. found that rs1800789 minor-allele homozygotes had reduced carotid intima-media thickness (Exp.β=0.89), a validated noninvasive marker of subclinical atherosclerosis that tracks closely with cardiovascular event risk.

Mechanistic support comes from a South African cohort study of 2,010 Tswana individuals⁵⁵ a South African cohort study of 2,010 Tswana individuals
Cronjé HT et al. Fibrinogen and clot-related phenotypes determined by fibrinogen polymorphisms: Independent and IL-6-interactive associations. PLoS One. 2017;12(10):e0186508., which found rs1800789 significantly associated with fibrinogen concentration and altered clot architecture. Notably, the associations were modulated by IL-6 concentrations, consistent with the variant's proposed role as a regulator of the IL-6-driven acute-phase upregulation of FGB transcription.

The protective effect is nonetheless more modest and less consistently replicated than the risk alleles of rs1800787 and rs1800790 — the Greek CAD study used a relatively small sample, and larger replication datasets specifically for rs1800789 are lacking. This places the evidence at moderate strength.

Practical Actions

For the majority of people who carry two copies of the common G allele (GG), fibrinogen levels are not influenced by this locus and cardiovascular risk through this pathway is not modified. A allele carriers — especially AA homozygotes — may benefit from genuinely lower baseline fibrinogen, which could translate to modestly reduced thrombotic and atherosclerotic risk. The practical implication is primarily informational: this genotype provides useful context when interpreting measured fibrinogen levels (AA carriers may have constitutively lower levels that do not require intervention, and GG carriers receive no protection from this locus).

Given the strong LD between rs1800789 and its sibling variants, the cardiovascular protective signal seen here partly overlaps with the risk signals documented for rs1800787 and rs1800790. Users carrying the A allele at rs1800789 will often be on the lower-fibrinogen haplotype at all three sites simultaneously.

Interactions

rs1800789 sits in a haplotype block in the FGB promoter region that also includes rs1800787 (-148C>T) and rs1800790 (-455G>A). In European populations, these three variants are in moderate-to-strong linkage disequilibrium, and the CAD-protective minor alleles at rs1800789 tend to co-occur with the lower-risk haplotype at the other sites. The combined haplotype effect on fibrinogen levels is larger than any single variant alone. Individuals carrying minor alleles at all three promoter sites are likely on the lowest- fibrinogen FGB haplotype in European ancestry populations.

The IL-6 interaction documented in the Cronjé study is particularly relevant to inflammatory conditions: carriers of the A allele may mount a smaller fibrinogen surge during acute illness, infection, or major surgery compared to GG homozygotes — a potentially protective effect in high-inflammatory-stress contexts.